TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07659782: A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

Sponsor: Verastem, Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 105 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,557,400

Rescue Site Savings

+$2,356,200

Unlock Full NCT07659782 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07659782 Rescue Dossier →